An interventional study of CAR-T in Connective Tissue Diseases, sponsored by Guangzhou Bio-gene Technology Co., Ltd. Withdrawn at 1 site in China. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Guangzhou Bio-gene Technology Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Connective Tissue Diseases with a site in China — 13 open to participants now, 18 under way, 7 of them phase 3. Connective Tissue Diseases · China.
Among the 27 studies in Connective Tissue Diseases with a site in China, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is the only one with no phase, and was the 25th registered.
192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.
Browse Connective Tissue Diseases studies →13 of the 27 studies in Connective Tissue Diseases with a site in China are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in China, United States, Argentina and 8 more countries
Ages 18+
GlaxoSmithKline · Sites in China, United States, Argentina and 15 more countries
Ages 18+
Tongji Hospital · Sites in China
Ages 18+
Beijing Hospital · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 1 Year to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8 · Phase 4 6
First in 2014; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 224 across the 22 interventional studies, 150 across the 5 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 27 have an industry lead sponsor. The 10 most frequent:
Guangzhou Bio-gene Technology Co., Ltd is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Guangzhou Bio-gene Technology Co., Ltd has 1 study filed under Connective Tissue Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Connective Tissue Diseases with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07184814China-Japan Friendship HospitalClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Connective Tissue Diseases with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously diagnosed with one of the following diseases and meeting the corresponding latest international classification/diagnostic criteria :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The dosage range of 1.0 × 10\^6/kg (± 20%) to 3.0 × 10\^6/kg (± 20%) of CAR-T cells, administered intravenously.
Biological: CAR-T
Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
Evaluation of Safety
Count the Incidence of adverse events
Time frame: Up to 2 years after CAR-T infusion
Effectiveness evaluation
The response rate of the responder index of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (scleroderma SSc), Sjogren's Syndrome, polymyositis/dermatomyositis, and mixed connective tissue disease (MCTD), as well as the changes in scores compared with the baseline value
Time frame: Up to 2 years after CAR-T infusion
Pharmacokinetic parameters
The highest concentration of CAR-T cell expansion in peripheral blood after administration.
Time frame: Up to 2 years after CAR-T infusion
Pharmacodynamic parameters
The peak values of CAR-T-related cytokines, which include at least IL-6 and IFN-γ.
Time frame: Up to 2 years after CAR-T infusion
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2025 to primary completion in Mar 2026, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangzhou Bio-gene Technology Co., Ltd